US pauses use of Eli Lilly Covid-19 mAb combo in six more states due to variants from Brazil, India
As the combined frequency of the Covid-19 variants first identified in Brazil and South Africa now exceeds 10% in Arizona, California, Florida, Indiana, Oregon and Washington, the US said Wednesday that it’s halting all shipments to those states of Eli Lilly’s mAb combo to treat Covid-19 prior to hospitalizations.
The FDA recommends that health care providers in those six states use Regeneron’s mAb cocktail as an alternative authorized monoclonal antibody therapy because it’s more effective against the variants than the Lilly treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
